Catabasis Pharmaceuticals Announces Promotion of Ted Hibben to Chief Business Officer
Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB), a clinical-stage biopharmaceutical company, today announced the
promotion of Ted Hibben to Chief Business Officer. Mr. Hibben has more than 20 years of experience in business and corporate
development, strategy, fundraising and M&A. Mr. Hibben joined Catabasis in 2015 and previously served as Senior Vice President,
Corporate Development.
“Ted has a successful track record of building value with innovative product platforms, an ideal fit for our SMART linker
platform. The SMART linker platform has already produced product candidates in multiple disease areas, creating opportunities for
licensing as well as collaboration,” said Jill C. Milne, Chief Executive Officer of Catabasis. “Ted has been a significant
contributor to the Catabasis executive team and we look forward to his further leadership in the Chief Business Officer role and
his impact on our corporate strategy.”
Prior to joining Catabasis, Mr. Hibben was Senior Vice President, Corporate Development at Ensemble Therapeutics, where he
formed four multi-target discovery and development-stage collaborations with pharmaceutical companies, generating over $1 billion
in potential milestone payments for programs emerging from Ensemble’s macrocycle library platforms. Previously, Mr. Hibben was
Chief Business Officer at Cequent Pharmaceuticals, where he played an instrumental role in its 2010 merger with MDRNA, Inc. (now
Marina Biotech), and was Vice President, Business Development and Alliance Management at Coley Pharmaceutical Group, where he
sourced and/or managed nine development alliances and led the sale of Coley to Pfizer in 2008. Ted holds an MBA from Harvard
University and an AB from Dartmouth College.
About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our SMART
(Safely Metabolized And Rationally Targeted) linker drug discovery platform enables us to engineer molecules that simultaneously
modulate multiple targets in a disease. We are applying our SMART linker platform to build an internal pipeline of product
candidates for rare diseases and plan to pursue partnerships to develop additional product candidates. For more information on the
Company's drug discovery platform and pipeline of drug candidates, please visit www.catabasis.com.
Catabasis Pharmaceuticals, Inc.
Andrea Matthews, 617-349-1971
amatthews@catabasis.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170217005076/en/